Platform using newly discovered stem cell–like memory T cells to create CAR‑T therapies with improved durability, safety, and flexibility for mono‑ or multi‑specific oncology targets. Same cell platform is being developed to generate HIV‑resistant T cells by removing the viral receptor to rebuild durable, infection‑resistant T‑cell repertoires in HIV patients.